Your session is about to expire
← Back to Search
Quadruple Therapy for Multiple Myeloma (ADVANCE Trial)
ADVANCE Trial Summary
This trial is testing whether two different treatments for multiple myeloma are safer and more effective than the current standard of care.
ADVANCE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowADVANCE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 126 Patients • NCT03029234ADVANCE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am able to care for myself and perform daily activities.I do not have severe stomach issues, nerve pain, drug allergies, or recent major surgery.I do not have HIV, hepatitis B or C, or active COVID-19.I have conditions like leukemia, COPD, high blood pressure, or diabetes that are not well-controlled.I have been recently diagnosed with Multiple Myeloma.I am able to have children, not pregnant, and use birth control.I have taken certain medications or undergone specific treatments before.My blood, kidney, liver, and heart are functioning well.I have a serious heart condition or recently had a heart attack.My condition has caused damage to my organs or meets specific criteria for myeloma.I can undergo treatments to prevent blood clots.I have had more than one treatment cycle for my multiple myeloma.I am between 18 and 75 years old.I agree to use a latex condom during sex with a female capable of becoming pregnant.
- Group 1: Arm A - Bortezomib, Lenalidomide and Dexamethasone (VRD)
- Group 2: Arm C- Carfilzomib, Lenalidomide and Dexamethasone with Daratumumab (DKrd)
- Group 3: Arm B - Carfilzomib, Lenalidomide and Dexamethasone (KRD)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are minors being considered for inclusion in the experimental trial?
"This trial is open to individuals aged 18 and over, up until they reach 75 years of age."
How many individuals are partaking in this clinical research program?
"For the trial to move forward, 306 participants meeting all necessary inclusion criteria must be recruited. Janssen Pharmaceuticals will facilitate this endeavour from their respective sites in Houston and Chicago; MD Anderson Cancer Center and Rush University Medical Centre respectively."
Has Carfilzomib been sanctioned by the Federal Drug Administration?
"Carfilzomib's safety has been partially assessed through a Phase 2 trial, leading to an estimation of security at level two on the 1-3 scale. No data exists in regards to efficacy yet."
What other research has been done using Carfilzomib as a therapeutic agent?
"Presently, there are 894 ongoing clinical studies exploring the effects of Carfilzomib with 202 trials in their final phase. Most studies take place in Joliet, Illinois however global participation is strong; over 27 thousand different places have hosted a trial for this medication."
Could I potentially qualify to participate in this experiment?
"To take part in this clinical trial, potential participants must meet the age criteria of 18-75 and be diagnosed with multiple myeloma. The sheer number of patients that are being admitted is 306."
Are there a variety of sites conducting this medical experiment in the city?
"This clinical trial is recruiting participants from 11 sites including MD Anderson Cancer Center in Houston, Texas; Rush University Medical Center in Chicago, Illinois; and Stony Brook University in Stony Brook, New york."
In what cases is Carfilzomib regularly prescribed?
"Carfilzomib is a common medication to manage macular edema, but it can also be beneficial in treating eye inflammation and viral retinal necrosis associated with varicella-zoster. Additionally, Carfilzomib has been used for ulcerative colitis when other treatments have failed."
Are recruitment efforts ongoing for this experiment?
"Affirmative. Clinicaltrials.gov shows that this medical study, initially posted on February 11th 2020, is still seeking participants. A total of 306 people need to be recruited from 8 distinct sites."
Share this study with friends
Copy Link
Messenger